In-Depth Review on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Complete report available @ Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 14, 10, 70, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 22 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AbbVie Inc Absynth Biologics Ltd Actelion Ltd Adenium Biotech ApS Alchemia Ltd Allergan Plc AmpliPhi Biosciences Corp Antibiotx ApS Aphios Corp Aridis Pharmaceuticals LLC AstraZeneca Plc Atriva Therapeutics GmbH Bavarian Nordic A/S Bharat Biotech International Ltd C3J Therapeutics Inc Cellceutix Corp Cempra Inc Citius Pharmaceuticals Inc Common Pharma Inc ContraFect Corp Crestone Inc Critical Outcome Technologies Inc CrystalGenomics Inc CytaCoat AB Daiichi Sankyo Company Ltd Debiopharm International SA Dermala Inc DesignMedix Inc Destiny Pharma Ltd Dong-A Socio Holdings Co Ltd Emergent BioSolutions Inc Ensol Biosciences Inc Galapagos NV GangaGen Inc Helix BioMedix Inc Hsiri Therapeutics LLC Ildong Pharmaceutical Co Ltd Immupharma Plc iNtRON Biotechnology Inc ioGenetics Inc Kyorin Pharmaceutical Co Ltd Lead Discovery Center GmbH LegoChem Biosciences Inc Lipocure Ltd Madam Therapeutics BV Melinta Therapeutics Inc Merck & Co Inc Microbiotix Inc MicuRx Pharmaceuticals Inc MorphoSys AG Motif Bio Plc Nabriva Therapeutics AG Nemus Bioscience Inc Novabiotics Ltd NovaDigm Therapeutics Inc Novalex Therapeutics Inc NovoBiotic Pharmaceuticals LLC Oragenics Inc Ovensa Inc Pfizer Inc Phico Therapeutics Ltd Prommune Inc Recce Ltd Savara Inc Sealife PHARMA GMBH Soligenix Inc Sorrento Therapeutics Inc Taejoon Pharm Co Ltd TAXIS Pharmaceuticals Inc Telephus Medical LLC Tetraphase Pharmaceuticals Inc Theravance Biopharma Inc Trellis Bioscience Inc Valevia UK Ltd VLP Biotech Inc Wockhardt Ltd XBiotech Inc Yungjin Pharm Co Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###